The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
M | Musculo-skeletal system | |
2
|
M01 | Antiinflammatory and antirheumatic products | |
3
|
M01A | Antiinflammatory and antirheumatic products, non-steroids | |
4
|
M01AE | Propionic acid derivatives | |
5
|
M01AE17 | Dexketoprofen |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 75 mg | |
| PAREN | Parenteral | 75 mg |
| Active Ingredient |
|---|
|
Dexketoprofen belongs to the non-steroidal anti-inflammatory group of drugs. The mechanism of action of Dexketoprofen is related to the reduction of prostaglandin synthesis by the inhibition of cyclooxygenase pathway. Furthermore, the inhibition of the synthesis of prostaglandins could affect other inflammation mediators such as kinins, causing an indirect action which would be additional to the direct action. |
| Document | Type | Information Source | |
|---|---|---|---|
| KERAL Film-coated tablet | MPI, EU: SmPC | Medicines Authority (MT) | |
| KERAL Solution for injection/infusion | MPI, EU: SmPC | Medicines Authority (MT) | |
| KETESSE Film-coated tablets | MPI, Generic | Health Products Regulatory Authority (ZA) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.